The Organic Chemistry of Drug Synthesis, Volume 5

The seventh volume in The definitive series that provides a quick yet thorough overview of the synthetic routes used to access specific classes of therapeutic agents, this volume covers approximately 220 new non-proprietary drug entities introduced since the publication of Volumes 6. Many of these compounds represent novel structural types first identified by sophisticated new cell-based assays. Specifically, a significant number of new antineoplastic and antiviral agents are covered.

Daniel Lednicer, PhD, was a project officer at the National Cancer Institute